scholarly journals Necrotizing fasciitis caused by the treatment of chronic non-specific back pain

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Lilit Floether ◽  
Michael Bucher ◽  
Ralf Benndorf ◽  
Anna-Maria Burgdorff
Keyword(s):  
Back Pain ◽  
Chronic Back Pain ◽  
Intrathecal Injection ◽  
Local Anaesthetics ◽  
Term Therapy ◽  
Negative Effects ◽  
Case Presentation ◽  
Long Term Therapy

Abstract Background Chronic back pain is a multifactorial disease that occurs particularly in adults and has many negative effects on the quality of daily life. Therapeutic strategies are often multimodal and designed for a long-term therapy period. In some cases, one option is joint infiltration or intrathecal injection with local anaesthetics. An adverse effect of this intervention may be necrotic fasciitis, a disease with high mortality and few therapeutic options. Case presentation This case shows a 53-year-old female patient who developed necrotic fasciitis after infiltrations of the sacroiliac joint and after epidural-sacral and intrathecal injections. Conclusion Thanks to early and aggressive surgical intervention, antibiotic treatment and hyperbaric oxygenation, she survived this serious complication and was able to return to life.

Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy

2017 ◽  
Vol 21 (3) ◽  
pp. 565-569 ◽  
Author(s):  
Tanja Kraus ◽  
Kathrin Gegenleitner ◽  
Martin Svehlik ◽  
Michael Novak ◽  
Gerhardt Steinwender ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cerebral Palsy ◽  
Intrathecal Baclofen ◽  
Spastic Cerebral Palsy ◽  
Term Therapy ◽  
Long Term Therapy

scholarly journals Ultrasound-guided Perineural Dextrose Injection for Treatment of Superior Cluneal Nerve Entrapment: Serial Case Report

2021 ◽  
Vol 14 (1) ◽  
pp. 32-37
Author(s):  
Yusak M. T. Siahaan ◽  
Jessica Herlambang ◽  
Cynthia Putri ◽  
Pamela Tiffani
Keyword(s):  
Nerve Entrapment ◽  
Term Therapy ◽  
High Morbidity ◽  
Case Presentation ◽  
Therapeutic Modalities ◽  
Lower Back ◽  
Perineural Injection ◽  
Significant Clinical Improvement ◽  
Long Term Therapy

Background: Superior cluneal nerve entrapment is a neuropathic condition caused by the inclusion of the superior cluneal nerve that contributes to one of the causes of lower back pain leading to high morbidity. Several therapeutic modalities are available for superior cluneal nerve entrapment, including medications, physiotherapy, perineural injection, and surgery. Perineural injection with 5% dextrose has become therapeutic alternative in many cases of neuropathy, but its long-term effectiveness is unknown. Case Presentation: This study described four patients with superior cluneal nerve entrapment with severe pain intensity treated with ultrasonography guided perineural 5% dextrose injection, resulting in significant clinical improvement during the 6-month evaluation. Conclusion: Perineural injection can be considered as long-term therapy in patients with superior cluneal nerve entrapment who have failed other conventional therapies.

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Blood ◽  
2011 ◽  
Vol 118 (17) ◽  
pp. 4554-4560 ◽  
Author(s):  
Fabio Efficace ◽  
Michele Baccarani ◽  
Massimo Breccia ◽  
Giuliana Alimena ◽  
Gianantonio Rosti ◽  
...  
Keyword(s):  
Quality Of Life ◽  
General Population ◽  
Myeloid Leukemia ◽  
Term Therapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Long Term Therapy

Abstract The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: −22.6 (P < .001), −22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.

scholarly journals Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats

2007 ◽  
Vol 21 (4) ◽  
pp. 293-297 ◽  
Author(s):  
Carlos Augusto Nassar ◽  
Patricia Oehlmeyer Nassar ◽  
Denise Carleto Andia ◽  
Morgana Rodrigues Guimarães ◽  
Maria Teresa Pepato ◽  
...  
Keyword(s):  
Serum Levels ◽  
Cardiovascular Complications ◽  
Term Therapy ◽  
Control Group ◽  
Post Transplantation ◽  
Tacrolimus Therapy ◽  
Biochemical Evaluation ◽  
Long Term Therapy

One of the more serious complications following transplantation is the development of post-transplantation diabetes mellitus (PTDM), which has a major impact on the quality of life, with effects ranging from the control of glycemia times to increased susceptibility to infections and cardiovascular complications. It has been suggested that immunosuppressive therapy, mainly tacrolimus therapy, may be an important factor in the development of PTDM. There is a lack of studies that explore the effects of long-term tacrolimus on PTDM in animal protocols. The objective of this study was therefore to evaluate the effects of long-term therapy with tacrolimus in rats. One group was treated with tacrolimus, injected subcutaneously, in a daily dose of 1 mg/kg of body weight. The chosen dose was sufficient to achieve therapeutic tacrolimus serum levels. The experimental periods were 60, 120, 180 and 240 days. One group was used as control and received daily subcutaneous injections of saline solution during all periods. A tendency towards increased glycemia levels during the initial periods (60 and 120 days) was observed. However, at 180 and 240 days, the glycemia levels were not statistically different from that of the control group of the same period. It may thus be concluded that the deleterious effects of tacrolimus therapy on glycemia may be a time-related side effect.

scholarly journals Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis

2020 ◽  
Vol 9 (1) ◽  
pp. 154 ◽  
Author(s):  
Fabio Barra ◽  
Carolina Scala ◽  
Umberto Leone Roberti Maggiore ◽  
Simone Ferrero
Keyword(s):  
Quality Of Life ◽  
Oral Treatment ◽  
Fourth Generation ◽  
Term Therapy ◽  
Deep Endometriosis ◽  
Wide Range ◽  
Intestinal Symptoms ◽  
Long Term Therapy

Background: Rectosigmoid endometriosis is a severe form of deep endometriosis, which may be responsible for pain symptoms and a wide range of intestinal complains such as diarrhea, constipation, and abdominal cramping. The primary objective of this study was to evaluate the efficacy of long-term therapy with dienogest (DNG), a fourth-generation progestin, for ameliorating quality of life, pain, and intestinal symptoms of patients affected by rectosigmoid endometriosis. Methods: A retrospective analysis of a prospectively collected database was done on patients with endometriotic nodules infiltrating at least the muscular layer of the rectosigmoid wall with an estimated colorectal stenosis <60%. The diagnosis of rectosigmoid endometriosis was based on transvaginal ultrasonography. Patients accepting to participate in the study received continuous oral treatment with DNG at the dose of 2 mg/day. Results: At the end of the first year of treatment, a significant decrease in dysmenorrhea (P < 0.001), chronic pelvic pain (P < 0.001), dyspareunia (P < 0.001), dyschezia (P < 0.001), and in intestinal symptoms (P < 0.001) was observed. A progressive increase of the Endometriosis Health Profile-30 (EHP-30) and Gastrointestinal Quality of Life Index (GIQLI) scores was observed in the first two years of therapy (P < 0.001 and P < 0.001, respectively). Improvements of patients’ symptoms and quality of life were maintained until the end of the study. The regimen was well tolerated, and the frequency and amount of irregular bleeding decreased as treatment progressed. Conclusion: The current study confirms the efficacy of long-term therapy with DNG for treating symptoms caused by rectosigmoid endometriosis.

Sign in / Sign up

Export Citation Format

Share Document